GU Cancers 2022 | Recent advances in the treatment of upper tract urothelial carcinoma

Janet Kukreja, MD, MPH, University of Colorado, Boulder, CO, discusses recent advances in the treatment of upper tract urothelial carcinoma (UTUC), highlighting the investigation of FGFR inhibitors in clinical trials. In particular, FGFR3 is highly mutated in genomic analyses of UTUC, implying there would be efficacy if treated with an FGFR inhibitor such as erdafitinib. Dr Kukreja explains why adjuvant immunotherapy therapy may be appropriate for groups of patients, such as those with inadequate kidney function for treatment with cisplatin. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.